NEW DELHI -- U.S.-based Gilead Sciences has tied up with India's Cipla and Jubilant Life Sciences, Pakistan's Ferozsons Laboratories and two other generic pharmaceutical makers to ramp up the supply of remdesivir, its closely watched investigational coronavirus drug.
Pharmaceuticals
Gilead licenses remdesivir production to India and Pakistan
Royalty-free deals allow makers to distribute coronavirus drug to 127 countries
Remdesivir has been granted emergency use authorization to treat COVID-19 by the U.S. Food and Drug Administration. © Reuters
Read Next
.JPG?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
Latest on Pharmaceuticals
